Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.thromres.2016.11.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dabigatran as a Treatment Option for Heparin-Induced Thrombocytopenia.
J Clin Pharmacol
January 2019
Department of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Heparin-induced thrombocytopenia (HIT) is a potentially serious adverse drug reaction that can result in lethal vascular thrombosis. Dabigatran is a direct thrombin inhibitor that might be useful in the management of HIT. This study evaluated the efficacy and safety of dabigatran in patients with HIT.
View Article and Find Full Text PDFDabigatran-related platelet thrombin response during triple anti-thrombotic therapy: A matter of time?
Thromb Res
January 2017
Department of Cardiology, Charité Universitätsmedizin, Hindenburgdamm 30, 12203 Berlin, Germany. Electronic address:
Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events.
Thromb Res
April 2016
Coagulation Unit, Hematology Center, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden; Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada; Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada.
Background: Strategies used for the management of dabigatran-related major bleeding events (MBEs), and their effectiveness have not been systematically evaluated.
Methods: Reports on 1034 individuals experiencing 1121 MBEs (696 on dabigatran, and 425 on warfarin) in 5 phase III randomized controlled trials were assessed independently by two investigators.
Results: MBEs were managed either by drug discontinuation only (37%), or drug discontinuation with either transfusion of only red cell concentrates (38%), or plasma (23%).
Clinical experience of life-threatening dabigatran-related bleeding at a large, tertiary care, academic medical center: a case series.
J Med Toxicol
June 2014
UMass Memorial Medical Center, 55 Lake Ave. N, Worcester, MA, 01655, USA,
Introduction: Dabigatran, an oral direct thrombin inhibitor, is FDA approved for the prevention of stroke in patients with nonvalvular atrial fibrillation. No agent exists for the reversal of dabigatran-related major bleeding. Prothrombin complex concentrate (PCC) has been studied in reversal but was not shown to affect the surrogate markers of bleeding such as the thrombin time, ecarin clotting time, or activated partial thromboplastin time (aPTT).
View Article and Find Full Text PDFHemorrhagic complications associated with dabigatran use.
Clin Toxicol (Phila)
November 2012
New York City Poison Control Center, Bellevue Hospital Center, New York University, New York, NY 10016, USA.
Objective: Dabigatran is a direct thrombin inhibitor approved for anticoagulation in non-valvular atrial fibrillation and, in some countries, for thromboembolism prophylaxis following select orthopedic surgeries. Despite decreased rates of thromboembolism, bleeding remains a risk due to the inability to conveniently monitor anticoagulant effect and the lack of a reversal agent.
Case Series: We present four cases of dabigatran-related bleeding.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!